Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 4
1995 3
1996 6
1997 2
1998 3
1999 2
2000 1
2001 6
2002 7
2003 2
2004 8
2005 9
2006 9
2007 9
2008 10
2009 11
2010 7
2011 9
2012 6
2013 7
2014 5
2015 5
2016 3
2017 2
2018 1
2019 1
2020 2
2021 4
2022 1
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

130 results
Results by year
Filters applied: . Clear all
Page 1
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C, Kitjarak R. Anamnart C, et al. J Clin Neurosci. 2021 Jun;88:226-231. doi: 10.1016/j.jocn.2021.03.047. Epub 2021 Apr 20. J Clin Neurosci. 2021. PMID: 33992189 Clinical Trial.
The aim of this study was to evaluate whether Hcy levels are increased in levodopa-treated PD patients and to evaluate the effects of vitamin B12 and folate or entacapone on Hcy levels in levodopa-treated PD patients. METHODS: We analyzed and compared plasma Hcy levels in …
The aim of this study was to evaluate whether Hcy levels are increased in levodopa-treated PD patients and to evaluate the effects of vitami …
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Warren Olanow C, et al. Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29. Mov Disord. 2013. PMID: 23630119 Clinical Trial.
The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the …
The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy …
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, Sasson N, Caraco Y. Giladi N, et al. Parkinsonism Relat Disord. 2021 Oct;91:139-145. doi: 10.1016/j.parkreldis.2021.09.024. Epub 2021 Oct 1. Parkinsonism Relat Disord. 2021. PMID: 34619438 Free article. Clinical Trial.
During Period-2, 16 patients were randomized to receive 7 days treatment with ND0612 or ND0612 plus oral entacapone. Reduction in OFF time was analyzed as an exploratory measure using a futility design with a predefined margin of 1.6 h. ...Patients treated with adjunct ND0 …
During Period-2, 16 patients were randomized to receive 7 days treatment with ND0612 or ND0612 plus oral entacapone. Reduction in OFF …
Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA. Hauser RA. Neurology. 2004 Jan 13;62(1 Suppl 1):S64-71. doi: 10.1212/wnl.62.1_suppl_1.s64. Neurology. 2004. PMID: 14718682 Clinical Trial.
Most PD patients taking levodopa/carbidopa immediate-release (IR) plus entacapone can be directly switched to the corresponding dose Stalevo product. For fluctuating PD patients taking levodopa/carbidopa IR without entacapone, switching to the corresponding Stalevo …
Most PD patients taking levodopa/carbidopa immediate-release (IR) plus entacapone can be directly switched to the corresponding dose …
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators. Ferreira JJ, et al. Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23. Lancet Neurol. 2016. PMID: 26725544 Clinical Trial.
We aimed to assess the safety and efficacy of opicapone as an adjunct to levodopa compared with placebo or entacapone in patients with Parkinson's disease and motor fluctuations. ...Serious adverse events were reported in six patients in the placebo group, eight in the …
We aimed to assess the safety and efficacy of opicapone as an adjunct to levodopa compared with placebo or entacapone in patients wit …
Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
Trenkwalder C, Kuoppamäki M, Vahteristo M, Müller T, Ellmén J. Trenkwalder C, et al. Neurology. 2019 Mar 26;92(13):e1487-e1496. doi: 10.1212/WNL.0000000000007173. Epub 2019 Mar 1. Neurology. 2019. PMID: 30824559 Free PMC article. Clinical Trial.
OBJECTIVE: To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve "off" time in fluctuating Parkinson disease (PD) compared to the st …
OBJECTIVE: To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, …
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.
Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A. Kaakkola S, et al. Neurology. 1994 Jan;44(1):77-80. doi: 10.1212/wnl.44.1.77. Neurology. 1994. PMID: 8290096 Clinical Trial.

The area under the curve (AUC) of levodopa increased by 38% (p < 0.01) after administration of a single dose of entacapone and by 40% (p < 0.05) after 7 days of multiple dosing with entacapone. ...Four patients became slightly more dyskinetic during entacap

…

The area under the curve (AUC) of levodopa increased by 38% (p < 0.01) after administration of a single dose of entacapone and by

…
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
Ruottinen HM, Rinne UK. Ruottinen HM, et al. Clin Neuropharmacol. 1996 Aug;19(4):283-96. doi: 10.1097/00002826-199619040-00001. Clin Neuropharmacol. 1996. PMID: 8828991 Clinical Trial.
Entacapone brought about a dose-dependent decrease in S-COMT activity in the RBCs, maximally by 48% at 400 mg. ...Entacapone prolonged the duration of the motor response to levodopa by 33 min (p = 0.04) and dyskinesias by 45 min (p = 0.003) without affecting their m …
Entacapone brought about a dose-dependent decrease in S-COMT activity in the RBCs, maximally by 48% at 400 mg. ...Entacapone p …
Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.
Yadav M, Dixit P, Trivedi V, Gandhi A, Senger A, Guttikar S, Singhal P, Shrivastav PS. Yadav M, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):533-40. doi: 10.1016/j.jchromb.2009.01.004. Epub 2009 Jan 13. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19167276 Clinical Trial.
A selective, sensitive and high throughput liquid chromatography-tandem mass spectrometry (LC-ESI-MS/MS) method has been developed and validated for the chromatographic separation and quantitation of (E)-entacapone and (Z)-entacapone in human plasma. Sample clean-up …
A selective, sensitive and high throughput liquid chromatography-tandem mass spectrometry (LC-ESI-MS/MS) method has been developed and valid …
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.
Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A. Illi A, et al. Clin Pharmacol Ther. 1995 Aug;58(2):221-7. doi: 10.1016/0009-9236(95)90200-7. Clin Pharmacol Ther. 1995. PMID: 7648772 Clinical Trial.
BACKGROUND: Entacapone is a potent, selective catechol-O-methyltransferase (COMT) inhibitor. Entacapone could potentiate the hemodynamic effects of exogenously administered catecholamines, which are substrates of the COMT enzyme. ...
BACKGROUND: Entacapone is a potent, selective catechol-O-methyltransferase (COMT) inhibitor. Entacapone could potentiate the h …
130 results